Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

814 - Prophylactic cranial irradiation in patients with extensive-stage small-cell lung cancer (ES-SCLC): an updated tertiary cancer centre experience

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Mahendra Naidoo

Citation

Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425

Authors

M. Naidoo1, F. Lin2, M. Jameson1, K. Shelly1, A. Srivastava1

Author affiliations

  • 1 Medical Oncology, Waikato Hospital, 3240 - Hamilton/NZ
  • 2 Medical Oncology, Waikato Hospital, 3200 - Hamilton/NZ
More

Resources

Abstract 814

Background

Prophylactic cranial irradiation (PCI) is the standard of care in patients who respond to initial chemotherapy for ES-SCLC, although several studies have questioned its benefit with regard to overall survival.

Methods

Here we report an updated result on a single-centred ES-SCLC cohort in a regional cancer centre in New Zealand. All ES-SCLC patients who had at least one cycle of chemotherapy from 2001 through April 2017 were included. The available records were reviewed to extract age, sex, comorbidities, metastatic sites, chemotherapy [regimen, and number of chemotherapy lines (NCL)], radiotherapy [palliative, consolidation chest radiotherapy (CCRT), or PCI], and overall survival (OS). Patients were stratified by PCI status (received vs. not received). Penalised regression was used for selecting variables for Cox’s regression, which was then used to adjust for confounders that affect survival by PCI status.

Results

Of 328 ES-SCLC patients evaluable, 295 received ≥1 cycle of chemotherapy. In the 68 patients (23%) who received PCI, the median OS was 14.0 months (95% CI: 11.2-16.6), compared to 5.8 months (95% CI: 4.9-7.1) in patients who did not receive PCI (unadjusted hazard ratio (HR) for death: 0.40, 95% CI: 0.30-0.53). After adjusting for three significant covariates (NCL, whether ≥4 cycles of first-line chemotherapy was given, and whether CCRT was delivered), patients who received PCI were found to have a significantly longer survival (adjusted HR: 0.63, 95% CI: 0.43-0.90). Patients (N = 109, 33%) who had <4 cycles of first-line chemotherapy (and later did not receive more chemotherapy) had a very poor prognosis (median OS: 2.93 months, 95%CI: 2.0-3.4).

Conclusions

ES-SCLC patients treated with PCI appear to have a better survival in our cohort, although this difference could be affected by lack of baseline cranial imaging to exclude patients with asymptomatic brain metastases. PCI should still be used judiciously considering its toxicities and potential negative impact on quality of life.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Waikato District Health Board.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.